# Aspreva Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aspreva-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Victoria, Canada
- Website: www.aspreva.com
- Total disclosed funding: $53M
- Latest round: Series A (Mar 9, 2004)
- Investors on record: 7

## About

Aspreva Pharmaceuticals specializes in developing and commercializing innovative treatments for rare diseases, focusing on addressing significant unmet medical needs with advanced therapeutic solutions.Aspreva Pharmaceuticals is dedicated to developing treatments for rare diseases. The company was headquartered in Victoria, Canada, and has made strides since its inception. In March 2005, Aspreva Pharmaceuticals closed its IPO, raising USD 79.20 mn. In December 2007, the company was acquired by Galenica. The company has engaged in four notable deals, with the most recent transaction occurring in March 2005.Aspreva Pharmaceuticals primarily focuses on innovative pharmaceutical solutions for rare diseases. Its leading product provides targeted therapies that enhance quality of life for patients with specific medical conditions. The company serves a diverse range of clients, including healthcare providers and research organizations, who utilize these solutions to better manage rare diseases and improve patient outcomes. The company’s products have garnered attention for their efficacy in addressing unique medical challenges.The company generates revenue through the sale of its pharmaceutical products, following a direct sales model that connects it with healthcare providers and facilities. Revenue is supplemented through strategic partnerships, which enhance product distribution and accessibility. Notably, Aspreva Pharmaceuticals has established a robust market presence, ensuring its therapies reach healthcare providers and patients requiring specialized treatments.Aspreva Pharmaceuticals aims to expand its product line by developing new therapies for additional rare diseases, with several candidates expected to enter clinical trials by 2023. The company plans to penetrate new markets in Europe and Asia, targeting specific regions to enhance accessibility to its treatments by 2024. The recent IPO funding of USD 79.20 mn will support these initiatives, focusing on research and development as well as market expansion efforts.

## Funding rounds

- Series A, Mar 9, 2004, $53M — GCM Grosvenor, InterWest Partners, Sprout Group, HBM Partners, BioAsia Investments, Axiom Venture Partners, Kearny Venture Partners

## Investors

- GCM Grosvenor — Series A
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- BioAsia Investments (https://capitalatlas.ai/funds/bioasia-investments) — Series A
- Axiom Venture Partners (https://capitalatlas.ai/funds/axiom-venture-partners) — Series A
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series A